Title: NOXXON Pharma AG
Description: Berlin-based NOXXON Pharma AG is a private clinical-stage biotechnology company focusing on the development of its proprietary substance class Spiegelmers® (L-aptamers) for the treatment of inflammatory diseases and hematological indications. The compan
Keywords:aptamer, L-aptamer, Spiegelmer, antibody, scaffold, nucleic acid, oligonucleotide, enantiomer, drug discovery, library, libraries, screening, SELEX, selection, in vitro selection, monocyte chemoattractant protein 1, MCP-1, chemokine, cytokine, chemokine C-C motif ligand 2, CCL2, CCR2, CCR4, NOX-E36, stroma cell-derived factor 1,
... (View More)
SDF-1, chemokine C-X-C motif ligand 12, CXCL12, CXCR4, fusin, NOX-A12, diabetes, type 2 diabetes, diabetes-related complications, diabetic nephropathy, kidney inflammation, lupus nephritis, NASH, nonalcoholic steatohepatitis, COPD, chronic obstructive pulmonary disease, stem cell transplantation, apheresis, multiple myeloma, non-Hodgkin’s lymphoma, mozobil, plerixafor, AMD3100, granulocyte colony-stimulating factor, GCSF, G-CSF, neupogen, filgrastim, lenograstim, bone marrow transplant(View Less)
+
0%) - 
